Drug delivery using terminal complement components

• US 6,066,319 A
• Filed: 04/30/1996
• Issued: 05/23/2000
• Est. Priority Date: 04/30/1996
• Status: Expired due to Fees

• Current Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Original Assignee: President and Fellows of Harvard College (Harvard Corporation)
• Inventors: Halperin, Jose A., Acosta, Juan A., Goldstein, Daniel J.
• Primary Examiner(s): Hutzell, Paula K.
• Assistant Examiner(s): DAVIS, MINH TAM B
• Application Number:
  US08/640,264
• Time in Patent Office: 1,484 Days
• Field of Search: 514/2, 514/44, 424/184.1, 424/236.1, 424/130.1, 530/387.1, 530/350, 536/22.1
• US Class Current: 424/130.1
• CPC Class Codes: A61K 38/04 Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof enzyme inhibitors A61K38/005; gastrins A61K38/2207, somatostatins A61K38/31, melanotropins A61K38/34 ; protease inhibitors A61K38/55
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 51/1203 in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors
• CPC Class Codes: A61K 51/1268 host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 33/00 Antiparasitic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• CPC Class Codes: C07K 16/00 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies antibodies with enzymatic activity, e.g. abzymes C12N9/0002
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• CPC Class Codes: G01N 33/536 with immune complex formed in liquid phase
• CPC Class Codes: G01N 33/56911 Bacteria
• CPC Class Codes: G01N 33/573 for enzymes or isoenzymes
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Methods for treatment of a subject with therapeutic or diagnostic agents by delivery of the therapeutic or diagnostic agents to the subject via sublytic amounts of terminal complement membrane attack acomplex (MAC) transmembrane channels are described. Also described are methods for delivery of therapeutic or diagnostic agents to cells in vitro via sublytic amounts of MAC transmembrane channels. Pharmaceutical preparations containing MAC transmembrane channel forming agents and kits for the formation of sublytic amounts of MAC transmembrane channels also are provided.

Claims

1. A method for treating a subject with a therapeutic or diagnostic agent comprising:

administering to a subject in need of such treatment an effective amount of a non-constitutive membrane attack complex (MAC) transmembrane channel forming agent to form a sublytic amount of MAC transmembrane channels in cells within said subject, and

administering substantially simultaneously therewith an effective amount of said therapeutic or diagnostic agent, said therapeutic or diagnostic agent being non-binding to said non-constitutive MAC transmembrane channel forming agent when said non-constitutive MAC transmembrane channel forming agent comprises an antibody.

2. A method as in claim 1 wherein said therapeutic or diagnostic agent is non-binding to said MAC transmembrane channel forming agent.

3. A method as in claim 1 wherein the MAC transmembrane channel forming agent selectively binds to predetermined target cells within the subject.

4. A method as in claim 3 wherein the target cells are cells of the subject.

5. A method as in claim 3 wherein the target cells are cells of an infectious agent within the subject.

6. A method as in claim 1 wherein the MAC transmembrane channel forming agent is isolated C5b-C6 complement protein complex.

7. A method as in claim 1 wherein the therapeutic or diagnostic agent is a therapeutic agent selected from the group consisting of polypeptides, oligonucleotides, toxins, antibiotics, antivirals, antiparasitics, antifungals and antineoplastics.

8. A method as in claim 1 wherein the therapeutic or diagnostic agent is a therapeutic oligonucleotide.